Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance

European Journal of Clinical Pharmacology

Volumn 54, Issue 12, 1999, Pages 943-946

  Spigset, O ^a,b   Hagg S ^a   Soderstrom E ^a   Dahlqvist, R ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Caffeine; CYP1A2; Fluvoxamine

Indexed keywords

CAFFEINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; KOFFEIN ACO; PHENACETIN O DEETHYLASE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CORRELATION FUNCTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SMOKING;

CAFFEINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; THEOPHYLLINE;

EID: 0033044370     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050579     Document Type: Article

References (29)

1. Nemeroff CB, Lindsay DeVane C, Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153: 311-320
2. Bertilsson L, Dahl M-L (1996) Polymorphic drug oxidation. CNS Drugs 5: 200-223
3. Sindrup SH, Brøsen K, Hansen MGJ, Aas-Jørgensen T, Overø KF, Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15: 11-17
4. Spigset O, Granberg K, Hägg S, Norström Å, Dahlqvist R (1997) Relationship between fluvoxamine pharmacokinetics and the CYP2D6/CYP2C19 polymorphisms. Eur J Clin Pharmacol 52: 129-133
5. Carrillo JA, Dahl M-L, Svensson J-O, Alm C, Rodríguez I, Bertilsson L (1996) Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60: 183-190
6. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Fur J Clin Pharmacol 51: 73-78
7. Sperber AD (1991) Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year old boy. Drug Saf 6: 460-462
8. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368-374
9. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R (1995) Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 58: 399-403
10. Hall M, Groocer PL (1990) Polycyclic aromatic hydrocarbons: metabolism, activation and tumor initiation. In: Cooper CS, Grover PL (eds) Chemical carcinogenesis and mutagenesis I. Springer, Berlin Heidelberg New York, pp 327-372
11. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3: 239-249
12. Spigset O, Granberg K, Hägg S, Söderström E, Dahlqvist R (1998) Non-linear fluvoxamine disposition. Br J Clin Pharmacol 45: 257-263
13. Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4: 109-116
14. Campbell MJ, Machin D (1993) Medical statistics, 2nd edn. Wiley, Chichester
15. Lelo A, Miners JO, Robson RA, Birkett DJ (1986) Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol 22: 183-186
16. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF (1989) Human cytochrome P-450pa (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 86: 7696-7700
17. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A (1991) Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 19: 561-567
18. Kalow W, Tang B-K (1993) The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53: 503-514
19. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW (1995) Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 39: 65-69
20. Tang B-K, Zhou Y, Kadar D, Kalow W (1994) Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 4: 117-124
21. Tang-Liu DD, Williams RL, Riegelman S (1983) Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 224: 180-185
22. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO (1992) Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2: 173-183
23. Eugster H-P, Probst M, Würgler FE, Sengstag C (1993) Caffeine, estradiol and progesterone interact with human CYP1A1 and CYP1A2. Drug Metab Dispos 21: 43-49
24. Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26: 363-372
25. Edwards RJ, Murray BP, Murray S, Schulz T, Neubert D, Gant TW, Thorgeirsson SS, Boobis AR, Davies DS (1994) Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis 15: 829-836
26. McKinnon RA, Hall PDLM, Quattrochi LC, Tukey RH, McManus ME (1991) Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 14: 848-856
27. Rothman N, Shields PG, Poirier MC, Harrington AM, Ford DP, Strickland PT (1995) The impact of glutathione s-tranferase M1 and cytochrome P4501A1 genotypes on white-blood-cell polycyclic aromatic hydrocarbon-DNA adduct levels in humans. Mol Carcinog 14: 63-68
28. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265: 401-407
29. Pastrakuljic A, Tang BK, Roberts EA, Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53: 531-538